,3 It selectively blocks MR overactivation, which drives inflammation and fibrosis—key contributors to CKD progression—while maintaining serum potassium concentration within an acceptable range, a known concern with steroidal MR antagonists.4 Here, NR3C2 is linked to chronic kidney disease.